Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

BACKGROUND: Farnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that there are several other potential targets for this drug class. The FTI tipifarnib (ZARNESTRA™, R115777) has recently demonstrated clinical responses in adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: Raponi, Mitch, Belly, Robert T, Karp, Judith E, Lancet, Jeffrey E, Atkins, David, Wang, Yixin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516036/
https://www.ncbi.nlm.nih.gov/pubmed/15329151
http://dx.doi.org/10.1186/1471-2407-4-56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516036/
https://www.ncbi.nlm.nih.gov/pubmed/15329151
http://dx.doi.org/10.1186/1471-2407-4-56

Ejemplares similares